Dergiler / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: Supplement 1

A Case of Resistant Hypocalcemia Treated with Teriparatide

Sayfa
92–93
Yayın Tarihi
2021-03-07
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Postsurgical chronic hypoparathyroidism is most commonly seen in adults.
📊
Temel Bulgular & Veri:Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions.
💡
Sonuç & Katkı:Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Hypoparathyroidism · Hypocalcemia · Teriparatide

Abstract

Postsurgical chronic hypoparathyroidism is most commonly seen in adults. Synthetic recombinant human parathyroid hormone (rhPTH) 1-34 can be used to stabilize serum calcium levels in patients with resistant hypocalcemia in rare conditions. Here we report a 52-year-old woman with postsurgical uncontrolled hypocalcemia despite the usual therapy. Once-daily treatment with PTH 1-34 maintained serum calcium within the normal range and reduced the dose of previous medical therapies.

🔖

Bu Makaleye Atıf Yap

AYDEMİR, E., ERSOY, C., GÜL, Ö. Ö., CANDER, S., ÜNSAL, Y. A., ATEŞ, C., ERTÜRK, E. (2021). A Case of Resistant Hypocalcemia Treated with Teriparatide. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: Supplement 1, 92–93. https://ajindex.com/articles/809089

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011
  2. 26(10):2317-2337. doi:10.1002/jbmr.483 Reference2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008
  3. 359(4):391-403. doi:10.1056/NEJMcp0803050 Reference3. Russell CF, Edis AJ. Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient. Br J Surg. 1982
  4. 69(5):244-247. doi:10.1002/bjs.1800690503 Reference4. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996
  5. 276(8):631-636. Reference5. Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med. 2019
  6. 380(18):1738-1747. doi:10.1056/NEJMcp1800213 Reference6. Gafni RI, Langman CB, Guthrie LC, et al. Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity. J Bone Miner Res. 2018
  7. 33(10):1741-1747. doi:10.1002/jbmr.3480 Reference7. Goujard C, Salenave S, Briot K, Chanson P, Grimon G, Kamenický P. Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns. Lancet. 2020
  8. 395(10232):1304. doi:10.1016/S0140-6736(20)30538-9